Relates to extending provisions of law relating to the New York state adult cystic fibrosis program until 2030.
Summary
S03320 is a short extender bill that changes the sunset date for New York’s adult cystic fibrosis assistance program. The bill amends chapter 769 of the laws of 2023, as previously amended in 2024, to replace the program’s current expiration date of March 31, 2025 with March 31, 2030. In practical terms, it keeps the underlying adult cystic fibrosis assistance program in place for an additional five years.
The bill does not create a new program or change eligibility, benefits, or administration details in the text provided. Its sole legal effect is to extend the life of the existing statutory authority so the program continues operating without interruption until the new sunset date. Because the measure is an amendment to the prior enabling law, it preserves the current framework for adult cystic fibrosis assistance unless changed by separate legislation.
Impact
The bill amends the expiration provision of the law governing New York’s adult cystic fibrosis assistance program, extending the statute’s effective period from March 31, 2025 to March 31, 2030. This keeps the program authorized under state law and prevents automatic repeal of the enabling provisions at the earlier date. The affected parties are adults living with cystic fibrosis who rely on the assistance program, along with the state agencies or administrators responsible for carrying it out.
Sentiment
The available context suggests a generally supportive or routine reauthorization measure, with no recorded votes or committee debate indicating opposition. Because the bill simply extends an existing health assistance program, it appears to be a low-conflict continuation bill rather than a controversial policy change. The absence of transcripts or voting history limits the ability to identify detailed positions, but the bill’s straightforward extender nature typically signals broad procedural support.
Contention
No specific points of contention are documented in the provided materials. The only substantive policy issue is whether the adult cystic fibrosis assistance program should continue beyond its current sunset date, and the bill answers that in favor of continuation. Without committee discussion or votes, there is no evidence of disagreement over eligibility, cost, program design, or the length of the extension.